Scope and limitations of MALDI-TOF MS blood serum peptide profiling in cancer diagnostics

[1]  M McCarthy,et al.  Hepatology , 1999, Rapid Medicine.

[2]  Lishu Cao.  Int J Cancer：戒烟可以改善恶性肿瘤患者预后 , 2017 .

[3]  Rajkumar Thangarajan,et al.  Identification of candidate biomarker mass (m/z) ranges in serous ovarian adenocarcinoma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling , 2015, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[4]  F. Kronenberg,et al.  Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies , 2014, Proteomics. Clinical applications.

[5]  C. Shannon-Weickert.  BIOMARKERS , 2014, Schizophrenia Research.

[6]  R. Karnes,et al.  A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria. , 2012, Mayo Clinic proceedings.

[7]  B. Nolen,et al.  Multianalyte assay systems in the differential diagnosis of ovarian cancer. , 2012, Expert opinion on medical diagnostics.

[8]  J. Blaakaer,et al.  The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. , 2012, Gynecologic oncology.

[9]  Kelly Bannister,et al.  Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women , 2012, Journal of Translational Medicine.

[10]  R. Molina,et al.  Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. , 2011, Clinical chemistry.

[11]  K. Sikaris,et al.  CA125--a test with a change of heart. , 2011, Heart, lung & circulation.

[12]  A. Kokcu.  Relationship between endometriosis and cancer from current perspective , 2011, Archives of Gynecology and Obstetrics.

[13]  R. Crawford,et al.  Endometriosis and Ovarian Cancer: A Systematic Review , 2011, ISRN obstetrics and gynecology.

[14]  J. Coon,et al.  Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non‐small cell lung cancer with circulating autoantibody biomarkers , 2011, International journal of cancer.

[15]  V. Govorun,et al.  New method for peptide desorption from abundant blood proteins for plasma/serum peptidome analyses by mass spectrometry. , 2011, Journal of proteomics.

[16]  M. Koyama,et al.  Ovarian fibroma with marked ascites and elevated serum levels of CA-125 in a young girl. , 2011, Journal of pediatric surgery.

[17]  Y. Suehara.  Proteomic analysis of soft tissue sarcoma , 2011, International Journal of Clinical Oncology.

[18]  B. Garcia,et al.  Proteomics , 2011, Journal of biomedicine & biotechnology.

[19]  Charles W Drescher,et al.  Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. , 2010, Gynecologic oncology.

[20]  T. Tomonaga,et al.  High-yield peptide-extraction method for the discovery of subnanomolar biomarkers from small serum samples. , 2010, Journal of proteome research.

[21]  J. Casal,et al.  Colorectal cancer proteomics, molecular characterization and biomarker discovery , 2010, Proteomics. Clinical applications.

[22]  F. Guadagni,et al.  Pre-analytical operating procedures for serum Low Molecular Weight protein profiling. , 2010, Journal of proteomics.

[23]  S. Chow,et al.  Analysis of protein profiles in human epithelial ovarian cancer tissues by proteomic technology. , 2010, European journal of gynaecological oncology.

[24]  L. Frati,et al.  HE4: a new potential early biomarker for the recurrence of ovarian cancer , 2010, Tumor Biology.

[25]  Sanjib Basu,et al.  Establishment of a Multi-Analyte Serum Biomarker Panel to Identify Lymph Node Metastases in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  F. Nezhat,et al.  The relationship of endometriosis and ovarian malignancy: a review. , 2008, Fertility and sterility.

[27]  Tadashi Kondo,et al.  Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. , 2008, BMB reports.

[28]  D. Ward,et al.  Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.

[29]  P. Stattin,et al.  SELDI‐TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case–control study of prostate cancer , 2007, International journal of cancer.

[30]  Y. Lio,et al.  Combined Staining of TAG-72, MUC1, and CA125 Improves Labeling Sensitivity in Ovarian Cancer , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[31]  T. Veenstra,et al.  The role of electrophoresis in disease biomarker discovery , 2007, Electrophoresis.

[32]  J. Albrethsen.  Reproducibility in protein profiling by MALDI-TOF mass spectrometry. , 2007, Clinical chemistry.

[33]  K. Hayashi,et al.  Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system , 2007, Hepatology.

[34]  E. Petricoin,et al.  Combination of SELDI-TOF-MS and Data Mining Provides Early-stage Response Prediction for Rectal Tumors Undergoing Multimodal Neoadjuvant Therapy , 2007, Annals of surgery.

[35]  J. Ji,et al.  Diagnosis of gastric cancer using decision tree classification of mass spectral data , 2007, Cancer Science.

[36]  Thomas A Neubert,et al.  Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry , 2006, Journal of Chromatography A.

[37]  G. Zheng,et al.  Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS. , 2006, Experimental oncology.

[38]  H. Kawasaki,et al.  Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma , 2006, Proteomics.

[39]  Shu Zheng,et al.  Application of serum protein fingerprint in diagnosis of papillary thyroid carcinoma , 2006, Proteomics.

[40]  Frank Vitzthum,et al.  Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics , 2006, Expert review of proteomics.

[41]  Xun Qu,et al.  Biomarker discovery for ovarian cancer using SELDI-TOF-MS. , 2006, Gynecologic oncology.

[42]  Liang Zhou,et al.  Detection of hypopharyngeal squamous cell carcinoma using serum proteomics , 2006, Acta oto-laryngologica.

[43]  P. Budde,et al.  Prerequisites for peptidomic analysis of blood samples: II. Analysis of human plasma after oral glucose challenge -- a proof of concept. , 2005, Combinatorial chemistry & high throughput screening.

[44]  W. Y. Zhang,et al.  Serum proteomic features for detection of endometrial cancer , 2005, International Journal of Gynecologic Cancer.

[45]  大房 健.  基礎講座 電気泳動(Electrophoresis) , 2005 .

[46]  Steven J Skates,et al.  Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[48]  E. Holland,et al.  Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.

[49]  M. Provencio,et al.  Cancer Antigen 125 Associated With Multiple Benign and Malignant Pathologies , 2003, Annals of Surgical Oncology.

[50]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[51]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[52]  M. Schrader,et al.  Composition of the peptide fraction in human blood plasma: database of circulating human peptides. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[53]  M. Karas,et al.  Suppression effects in enzymatic peptide ladder sequencing using ultraviolet ‐ matrix assisted laser desorption/ionization ‐ mass spectrometry , 1998, Electrophoresis.

[54]  R. Bast,et al.  Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. , 1984, Cancer research.

[55]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.